


## Accepted Manuscript

Title: Immunotherapy for Triple-Negative Breast Cancer:  
Existing Challenges and Exciting Prospects

Authors: Hongyan Jia, Cristina I. Truica, Bin Wang, Yanhong Wang, Xingcong Ren, Harold A. Harvey, Jianxuan Song, Jin-Ming Yang



PII: S1368-7646(17)30031-6  
DOI: <http://dx.doi.org/10.1016/j.drup.2017.07.002>  
Reference: YDRUP 605

To appear in: *Drug Resistance Updates*

Received date: 8-7-2017  
Revised date: 17-7-2017  
Accepted date: 20-7-2017

Please cite this article as: Jia, Hongyan, Truica, Cristina I., Wang, Bin, Wang, Yanhong, Ren, Xingcong, Harvey, Harold A., Song, Jianxuan, Yang, Jin-Ming, Immunotherapy for Triple-Negative Breast Cancer: Existing Challenges and Exciting Prospects. *Drug Resistance Updates* <http://dx.doi.org/10.1016/j.drup.2017.07.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Immunotherapy for Triple-Negative Breast Cancer: Existing Challenges and Exciting Prospects****Running title:** Immunotherapy and Triple-Negative Breast Cancer

Hongyan Jia<sup>1\*</sup>, Cristina I Truica<sup>4</sup>, Bin Wang<sup>1</sup>, Yanhong Wang<sup>5</sup>, Xingcong Ren<sup>2</sup>, Harold A Harvey<sup>4</sup>, Jianxuan Song<sup>3</sup> and Jin-Ming Yang<sup>2\*</sup>

<sup>1</sup>Department of General Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 03001 China;

<sup>2</sup>Department of Pharmacology, <sup>3</sup>Department of Microbiology and Immunology, and <sup>4</sup>Department of Medicine, the Penn State Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA;

<sup>5</sup>Department of Microbiology and Immunology Shanxi Medical University, Taiyuan, Shanxi, 03001, China

\*Address correspondence to: Hongyan Jia, Department of General Surgery, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China 03001, or Jin-Ming Yang, The Penn State College of Medicine, Department of Pharmacology and The Penn State Cancer Institute, CH74, 500 University Drive, P.O. Box 850, Hershey, PA 17033-0850

E-mail address: swallow\_jhy@163.com (H. Jia); juy16@psu.edu (J.M. Yang)

Tel: +86-13700515784 (H. Jia); +1-717-531-5959 (J.M. Yang)

**Abstract**

Patients with breast tumors that do not express the estrogen receptor, the progesterone receptor, nor Her-2/neu are hence termed “triple negatives”, and generally have a poor prognosis, with high rates of systemic recurrence and refractoriness to conventional therapy regardless of the choice of adjuvant treatment. Thus, more effective therapeutic options are sorely needed for triple-negative breast cancer (TNBC), which occurs in approximately 20% of diagnosed breast cancers. In recent years, exploiting intrinsic mechanisms of the host immune system to eradicate cancer cells has achieved impressive success, and the advances in

Download English Version:

<https://daneshyari.com/en/article/8436537>

Download Persian Version:

<https://daneshyari.com/article/8436537>

[Daneshyari.com](https://daneshyari.com)